Top Tips on Assessing Molecular Systems of Response
Add bookmark
Top Tips on Assessing Molecular Systems of Response
Add bookmark
Karol Sikora Medical Director at CancerPartners UK, joins Helen Winsor from Pharma IQ, to discuss new trial design approaches and biomarker application methods coming on stream to drive oncology clinical development. The main focus of this exclusive interview is on assessing molecular signatures of response. First of all, Sikora outlines the drug development pyramid, the main issues surrounding biomarkers and surrogate endpoints in cancer, and how we can evaluate mechanism driven biomarkers. The interview also covers the benefits of holistic approaches to biological sub-classification of disease, new methods being explored to enrich patient populations in phase III, and how we can potentially use biomarkers for life-cycle extension of current compounds.
[inlinead]
